All In Biotech

Drug Trial Radar · NCT06618001

A Study of JNJ-89853413 for Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Neoplasms

A Phase 1, First-in-Human, Dose Escalation Study of JNJ-89853413 for Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Neoplasms

Last checked: Nov 20, 2026Latest source record: Nov 3, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

64

Actual

Start

Jan 14, 2025

Primary completion

Sep 1, 2026

Study completion Sep 1, 2026

Sponsor

Lead sponsor
Janssen Research & Development, LLCJohnson & Johnson (Janssen) (JNJ)
Sponsor type
Industry
First posted
Oct 1, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Not applicable (single group)
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of Part 1 (Dose Escalation) of the study is to assess the safety and tolerability, and to identify the recommended Phase 2 dose\[s\] (RP2D\[s\]) in participants with relapsed or refractory (R/R) acute myeloid leukemia (AML) (that is a type of blood cancer that has come back after treatment/or has stopped responding to treatment) or R/R higher-risk type of myelodysplastic neoplasms (MDS, type of blood cancer). The purpose of Part 2 (Cohort Expansion) is to further assess the safety, tolerability and efficacy in participants with R/R AML or higher-risk types of MDS.

Conditions

  • Leukemia, Myeloid, Acute
  • Myelodysplastic Neoplasms

Interventions

  • JNJ-89853413Drug

    JNJ-89853413 will be administered.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Participants with Adverse events (AEs) by SeverityTime frame: From screening untill 30 days after last dose of study drug (that is approximately 2.5 years)
  2. Part 1: Number of Participants with Dose-Limiting Toxicity (DLTs)Time frame: 14 days

Locations

9 sites in 3 countries. Site status is shown where the registry gives one.

  • Arthur J E Child Comprehensive Cancer Centre

    Calgary, Alberta, Canada

  • Vancouver General Hospital

    Vancouver, British Columbia, Canada

  • Princess Margaret Hospital

    Toronto, Ontario, Canada

  • Hosp Clinic de Barcelona

    Barcelona, Spain

  • Hosp Univ Fund Jimenez Diaz

    Madrid, Spain

  • Clinica Univ. de Navarra

    Pamplona, Spain

  • Addenbrookes Hospital

    Cambridge, United Kingdom

  • University College London Hospitals

    London, United Kingdom

  • The Christie NHS Foundation Trust Christie Hospital

    Manchester, United Kingdom

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.